Spots Global Cancer Trial Database for multigated acquisition scan

Every month we try and update this database with for multigated acquisition scan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	NCT05564403	Recurrent Bilia... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage III Dista... Stage III Hilar... Stage III Intra... Stage IV Distal... Stage IV Hilar ... Stage IV Intrah... Unresectable Bi... Unresectable Di... Unresectable Ga... Unresectable In...	Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Leucovorin Calc... Magnetic Resona... Multigated Acqu... Oxaliplatin	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer	NCT03939897	Anatomic Stage ... Metastatic Brea... Metastatic HER2... Metastatic Horm... Recurrent Breas...	Abemaciclib Biopsy Biospecimen Col... Copanlisib Hydr... Diagnostic Imag... Echocardiograph... Fulvestrant Multigated Acqu...	18 Years -	National Cancer Institute (NCI)
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	NCT06210750	T Acute Lymphob... T Lymphoblastic...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging	18 Years - 60 Years	National Cancer Institute (NCI)
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer	NCT06287775	Extensive Stage... Stage IV Lung C...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Echocardiograph... Iadademstat Magnetic Resona... Multigated Acqu...	18 Years -	National Cancer Institute (NCI)
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	NCT04181060	Advanced Lung N... Metastatic Lung... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C...	Bevacizumab Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Osimertinib	18 Years -	National Cancer Institute (NCI)
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases	NCT06013423	Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid...	Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ...	6 Months - 65 Years	Fred Hutchinson Cancer Center
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes	NCT03399773	Acute Biphenoty... Acute Lymphobla... Chronic Myeloge... Hematopoietic a... Myelodysplastic... Myelodysplastic...	Dilanubicel Cyclophosphamid... Fludarabine Thiotepa Total-Body Irra... Umbilical Cord ... Laboratory Biom... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Multigated Acqu... Electrocardiogr... Computed Tomogr...	10 Years - 65 Years	Fred Hutchinson Cancer Center
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	NCT04557956	Clinical Stage ... Metastatic Mela...	Biopsy Computed Tomogr... Dabrafenib Mesy... Echocardiogram ... Magnetic Resona... Multigated Acqu... Tazemetostat Hy... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	NCT01989585	Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	NCT06151847	Clinical Stage ... Metastatic Mela... Pathologic Stag... Unresectable Me...	Biospecimen Col... Cyclophosphamid... Echocardiograph... Fludarabine Interleukin-2 Lifileucel Magnetic Resona... Multigated Acqu... Tumor Resection	18 Years - 70 Years	University of Kansas Medical Center
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer	NCT02345265	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian High Gr... Ovarian High Gr... Primary Periton... Primary Periton... Primary Periton...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	NCT06422806	Stage III Soft ... Stage IV Soft T... Undifferentiate...	Biospecimen Col... Diagnostic Imag... Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors	NCT01841736	Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest...	Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	NCT06126276	Malignant Femal... Malignant Solid... Recurrent Malig... Recurrent Malig...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Neratinib Malea... Palbociclib	18 Years -	National Cancer Institute (NCI)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	NCT06422806	Stage III Soft ... Stage IV Soft T... Undifferentiate...	Biospecimen Col... Diagnostic Imag... Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	NCT06249191	Diffuse Large B... High Grade B-Ce...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine	18 Years - 75 Years	OHSU Knight Cancer Institute
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	NCT05691504	Advanced Endome... Metastatic Endo... Metastatic Fall... Metastatic Plat... Metastatic Prim... Recurrent Endom... Recurrent Fallo... Recurrent Plati... Recurrent Prima... Stage III Uteri... Stage IV Uterin...	Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pelcitoclax	18 Years -	National Cancer Institute (NCI)
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations	NCT06043713	Metastatic Colo... Metastatic Lung... Metastatic Panc... Stage IV Colore... Stage IV Lung C... Stage IV Pancre...	Bendamustine Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Magnetic Resona... Multigated Acqu... Positron Emissi... T-cell Receptor...	18 Years -	Fred Hutchinson Cancer Center
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00557193	Acute Lymphobla... Acute Undiffere... Childhood T Acu...	Asparaginase Biospecimen Col... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Echocardiograph... Etoposide Filgrastim Laboratory Biom... Lestaurtinib Leucovorin Calc... Mercaptopurine Methotrexate Methylprednisol... Multigated Acqu... Pegaspargase Pharmacological... Prednisone Therapeutic Hyd... Vincristine Sul...	- 1 Year	Children's Oncology Group
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome	NCT06287944	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an...	18 Years -	City of Hope Medical Center
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	NCT04214249	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy	18 Years - 75 Years	National Cancer Institute (NCI)
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	NCT01947023	Metastatic Thyr... Unresectable Th...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	NCT05455697	Diffuse Large B... Grade 3b Follic... High Grade B-Ce...	Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved...	18 Years -	University of Washington
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)	NCT06124157	B Acute Lymphob...	Biospecimen Col... Blinatumomab Bone Marrow Bio... Calaspargase Pe... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Doxorubicin Echocardiograph... Leucovorin Mercaptopurine Methotrexate Multigated Acqu... Pegaspargase Prednisolone Prednisone Radiation Thera... Thioguanine Vincristine	366 Days - 46 Years	National Cancer Institute (NCI)
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	NCT06164275	Classic Hodgkin...	Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine	18 Years -	Northwestern University
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	NCT06164275	Classic Hodgkin...	Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine	18 Years -	Northwestern University
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma	NCT02339571	Stage III Cutan... Stage IV Cutane...	Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Multigated Acqu... Nivolumab Sargramostim	18 Years -	National Cancer Institute (NCI)
A Study Using a New Drug, Nivolumab, in Combination With Chemotherapy Drugs to Treat a Type of Cancer Called Nasopharyngeal Carcinoma (NPC)	NCT06064097	Stage II Nasoph... Stage III Nasop... Stage IV Nasoph...	Biopsy Biospecimen Col... Chest Radiograp... Cisplatin Computed Tomogr... Echocardiograph... Electronic Heal... Fluciclovine F1... Gemcitabine Magnetic Resona... Multigated Acqu... Nivolumab Positron Emissi... Quality-of-Life... Questionnaire A... Radiation Thera... X-Ray Imaging	- 21 Years	National Cancer Institute (NCI)
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT06054776	Mantle Cell Lym...	Acalabrutinib Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Echocardiograph... Glofitamab Multigated Acqu... Obinutuzumab Positron Emissi...	18 Years -	City of Hope Medical Center
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	NCT04375631	Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut...	Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp...	18 Years -	Fred Hutchinson Cancer Center
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer	NCT06094842	Prostate Carcin... Prostate Small ... Stage III Prost... Stage IV Prosta...	Bendamustine Biopsy Biospecimen Col... Bone Scan Bridge Therapy Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Multigated Acqu... T-cell Receptor... X-Ray Imaging	18 Years -	Fred Hutchinson Cancer Center
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	NCT02224781	Clinical Stage ... Clinical Stage ... Metastatic Mela... Recurrent Melan... Unresectable Me...	Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Echocardiograph... Ipilimumab Multigated Acqu... Nivolumab Quality-of-Life... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)	NCT05554354	Anatomic Stage ... Metastatic HER2... Metastatic Horm...	Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fulvestrant Magnetic Resona... Multigated Acqu...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene	NCT05886049	Acute Myeloid L... Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E...	18 Years - 75 Years	National Cancer Institute (NCI)
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	NCT01947023	Metastatic Thyr... Unresectable Th...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome	NCT05457556	Acute Lymphobla... Acute Myeloid L... Mixed Phenotype... Myelodysplastic...	Biospecimen Col... Bone Marrow Asp... Busulfan Cyclophosphamid... Echocardiograph... Fludarabine Haploidentical ... Lapine T-Lympho... Lumbar Puncture Matched Unrelat... Melphalan Methotrexate Multigated Acqu... Mycophenolate M... Myeloablative C... Quality-of-Life... Questionnaire A... Rituximab T-Cell Depletio... Tacrolimus Thiotepa Total-Body Irra...	6 Months - 21 Years	Children's Oncology Group
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	NCT06249191	Diffuse Large B... High Grade B-Ce...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine	18 Years - 75 Years	OHSU Knight Cancer Institute
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer	NCT04294628	Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	NCT06164275	Classic Hodgkin...	Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine	18 Years -	Northwestern University
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)	NCT04385277	Ganglioneurobla... Neuroblastoma	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab FDG-Positron Em... Iobenguane I-12... Irinotecan Isotretinoin Magnetic Resona... Multigated Acqu... Sargramostim Temozolomide	- 30 Years	Children's Oncology Group
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults	NCT04530565	B Acute Lymphob...	Biospecimen Col... Blinatumomab Bone Marrow Asp... Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Echocardiograph... Electrocardiogr... Lumbar Puncture Mesna Methotrexate Multigated Acqu... Ponatinib Hydro... Prednisone Vincristine Sul...	18 Years - 75 Years	National Cancer Institute (NCI)
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	NCT05564403	Recurrent Bilia... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage III Dista... Stage III Hilar... Stage III Intra... Stage IV Distal... Stage IV Hilar ... Stage IV Intrah... Unresectable Bi... Unresectable Di... Unresectable Ga... Unresectable In...	Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Leucovorin Calc... Magnetic Resona... Multigated Acqu... Oxaliplatin	18 Years -	National Cancer Institute (NCI)
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)	NCT04965597	Bone Marrow Fai... Congenital Ameg... Congenital Pure... Hereditary Side... Paroxysmal Noct... Shwachman-Diamo... Hematologic Neo... Hematologic Neo... Hematologic Neo...	Treosulfan Fludarabine Pho... Tacrolimus Methotrexate Lapine T-Lympho... Peripheral Bloo... Allogeneic Bone... Quality-of-Life... Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	1 Year - 49 Years	Fred Hutchinson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene	NCT05886049	Acute Myeloid L... Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E...	18 Years - 75 Years	National Cancer Institute (NCI)
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	NCT06128070	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Biospecimen Col... Chest Computed ... Echocardiograph... Hematopoietic C... Methotrexate Multigated Acqu... Ruxolitinib Pho... Tacrolimus	2 Years - 22 Years	City of Hope Medical Center
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer	NCT04294628	Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	NCT06343376	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Mantl... Recurrent Trans... Recurrent Trans... Refractory Chro... Refractory Diff... Refractory Foll... Refractory High... Refractory Mant... Refractory Tran... Refractory Tran...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... EGFRt/19-28z/IL... Fludarabine Pho... Leukapheresis Multigated Acqu... Positron Emissi...	18 Years -	Roswell Park Cancer Institute
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome	NCT06195891	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Dual-Energy Com... Echocardiograph... Fludarabine Magnetic Resona... Melphalan Multigated Acqu... Partially Engin... Tacrolimus Thiotepa Total Marrow an...	60 Years -	City of Hope Medical Center
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome	NCT06195891	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Dual-Energy Com... Echocardiograph... Fludarabine Magnetic Resona... Melphalan Multigated Acqu... Partially Engin... Tacrolimus Thiotepa Total Marrow an...	60 Years -	City of Hope Medical Center
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	NCT05691504	Advanced Endome... Metastatic Endo... Metastatic Fall... Metastatic Plat... Metastatic Prim... Recurrent Endom... Recurrent Fallo... Recurrent Plati... Recurrent Prima... Stage III Uteri... Stage IV Uterin...	Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pelcitoclax	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00557193	Acute Lymphobla... Acute Undiffere... Childhood T Acu...	Asparaginase Biospecimen Col... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Echocardiograph... Etoposide Filgrastim Laboratory Biom... Lestaurtinib Leucovorin Calc... Mercaptopurine Methotrexate Methylprednisol... Multigated Acqu... Pegaspargase Pharmacological... Prednisone Therapeutic Hyd... Vincristine Sul...	- 1 Year	Children's Oncology Group
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working	NCT05432791	Locally Advance... Metastatic Uter... Stage III Uteri... Stage IV Uterin... Unresectable Ut...	Biospecimen Col... Bone Scan Computed Tomogr... Magnetic Resona... Multigated Acqu... Olaparib Pazopanib Temozolomide Trabectedin Transthoracic E...	18 Years -	National Cancer Institute (NCI)
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome	NCT06287944	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an...	18 Years -	City of Hope Medical Center
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: